Sagimet's Denifanstat Shows Promise in Treating Fatty Liver Disease
Sagimet Biosciences announces positive topline results from its Phase 2b FASCINATE-2 clinical trial of denifanstat, a fatty acid synthase inhibitor, in NASH patients with stage 2 or 3 fibrosis. The trial showed statistically significant improvements in NASH resolution, fibrosis reduction, and liver health markers compared to placebo. Denifanstat was generally well-tolerated, with no treatment-related serious adverse events observed. The company plans to advance to Phase 3 development and aims to start in the second half of 2024.